Hone Bio

Hone Bio is a preclinical biotechnology company developing targeted lipid nanoparticle drug delivery technology.

Its proprietary platform uses engineered proteins that enable cell-specific LNP delivery while actively blocking off-target liver uptake, addressing a key limitation of conventional LNP systems.

The technology has potential applications across mRNA therapeutics, gene therapies, vaccines, and autoimmune diseases.

Hone Bio was originally founded as CytoSeek to develop artificial membrane-binding proteins for cell therapy, before pivoting to LNP targeting.